NASDAQ:BEAM - Beam Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $94.17
  • Forecasted Upside: 9.51 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$85.99
▲ +0.07 (0.08%)

This chart shows the closing price for BEAM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beam Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BEAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAM

Analyst Price Target is $94.17
▲ +9.51% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $94.17, with a high forecast of $145.00 and a low forecast of $33.00. The average price target represents a 9.51% upside from the last price of $85.99.

This chart shows the closing price for BEAM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Beam Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021Redburn PartnersInitiated CoverageBuyHigh
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$85.00High
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $90.00Low
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$47.00 ➝ $90.00Low
2/25/2021WedbushBoost Price Target$42.00 ➝ $112.00High
2/16/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00Low
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$38.00 ➝ $100.00Low
1/5/2021Stifel NicolausInitiated CoverageHoldN/A
10/16/2020WedbushReiterated RatingOutperform$40.00N/A
8/12/2020William BlairInitiated CoverageBuyN/A
8/5/2020William BlairReiterated RatingOutperform$33.00Medium
8/5/2020William BlairInitiated CoverageOutperform$33.00N/A
5/13/2020WedbushReiterated RatingOutperform$32.00N/A
3/2/2020WedbushReiterated RatingOutperformHigh
3/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$31.00N/A
3/2/2020WedbushInitiated CoverageOutperform ➝ Outperform$32.00 ➝ $32.00N/A
3/2/2020Jefferies Financial GroupInitiated CoverageBuy$32.00N/A
3/2/2020BarclaysInitiated CoverageOverweight$32.00N/A
(Data available from 6/23/2016 forward)
Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $85.99
Low: $83.52
High: $86.90

50 Day Range

MA: $77.52
Low: $64.12
High: $91.96

52 Week Range

Now: $85.99
Low: $18.76
High: $126.90

Volume

505,053 shs

Average Volume

958,329 shs

Market Capitalization

$5.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Beam Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Beam Therapeutics in the last year: Barclays PLC, JPMorgan Chase & Co., Redburn Partners, Royal Bank of Canada, Stifel Nicolaus, Wedbush, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BEAM.

What is the current price target for Beam Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Beam Therapeutics in the last year. Their average twelve-month price target is $94.17, suggesting a possible upside of 9.5%. Wells Fargo & Company has the highest price target set, predicting BEAM will reach $145.00 in the next twelve months. William Blair has the lowest price target set, forecasting a price of $33.00 for Beam Therapeutics in the next year.
View the latest price targets for BEAM.

What is the current consensus analyst rating for Beam Therapeutics?

Beam Therapeutics currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BEAM will outperform the market and that investors should add to their positions of Beam Therapeutics.
View the latest ratings for BEAM.

What other companies compete with Beam Therapeutics?

How do I contact Beam Therapeutics' investor relations team?

Beam Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-327-8775 and its investor relations email address is [email protected] The official website for Beam Therapeutics is www.beamtx.com.